Oura Targets Public Markets as Smaller Rings, Health Features Expand Its Consumer Reach

Oura has confidentially filed for a U.S. initial public offering as its smart rings move from a niche sleep product into a broader consumer health business. The Finland-founded company submitted a draft registration statement to the Securities and Exchange Commission, but it hasn't disclosed the number of shares, price range, or timing of the offering. The IPO depends on the SEC review and market conditions.

The filing gives investors a closer look at a company preparing for public scrutiny after rapid expansion. Oura's revenue rose 74% to $1.21 billion in the 9 months ended June 30, while net income reached $60.8 million, compared with $1.6 million a year earlier. Bloomberg reported that the filing also showed increasing losses, underscoring the tension between fast growth and the cost of scaling a hardware-and-subscription business.

Oura's appeal now extends beyond athletes and sleep enthusiasts. The ring tracks heart rate, sleep stages, physical activity, readiness, and other health signals, giving the company a broader pitch for people interested in daily wellness, prevention, and long-term health management. Its health features also include AI-powered tools focused on women's health.

That expansion supports Oura's effort to reach consumers who may not want a smartwatch on their wrist. The company has sold 5.5 million rings globally, more than double the 2.5 million figure previously reported, according to The Healthcare Technology Report. Oura Chief Medical Officer Dr. Ricky Bloomfield said the ring will help detect diseases, a claim that raises the product's medical ambitions as the company approaches public markets. The device's role remains centered on tracking and insight, while disease detection brings higher expectations for evidence, clinical validation, and regulatory discipline.

Oura's Ring 5 is designed to make the product easier to wear by shrinking the design 40% from the previous generation. The company says the smaller ring preserves the earlier model's sensing, tracking, and accuracy, despite the engineering challenge of fitting batteries, electronics, and sensors into less space.

The design change matters because comfort and appearance influence whether a wearable becomes a daily habit. Oura's chief executive, Tom Hale, said members had requested a smaller ring for years. A less bulky product also gives Oura a stronger answer to consumers comparing rings with watches and other wrist-based trackers. That hardware push complements the company's demographic expansion: health-conscious buyers, people focused on sleep, and users seeking discreet monitoring can all fit the same product strategy.

Oura's public-market story depends on more than unit sales. Smart rings combine upfront hardware costs with ongoing software and health insights, making pricing and subscription retention central to the company's economics. The available IPO coverage identifies the ring's cost as a key topic but doesn't provide a confirmed product price or subscription figure.

That leaves investors weighing Oura's revenue growth against the expense of research, manufacturing, data infrastructure, marketing, and clinical or health-related development. The company's jump from a $5 billion valuation in 2024 to an $11 billion valuation after a $875 million Series E round last year reflects strong private-market momentum. Its IPO filing now puts that momentum beside profitability metrics and operating losses, where the durability of customer spending will receive closer examination.

Oura has strengthened its board with 4 independent directors who bring public-company experience from businesses including Netflix and Robinhood. The appointments add governance expertise as the company prepares for an offering and transitions from private fundraising to quarterly reporting, shareholder scrutiny, and formal market disclosure.

The board expansion fits the wider timing of the filing. Oura entered the IPO process as consumer companies returned to public markets after a summer lull, with issuers targeting the period after Labor Day. For Oura, the move connects operating growth, product expansion, and corporate preparation. The company still has to clear the SEC review, set offering terms, and determine whether market conditions support a launch.

Oura's next phase will test whether a smart ring can sustain mainstream health adoption while meeting public investors' demands for profitable growth. The company has built scale through a discreet form factor, expanding health features, and a growing installed base, but its IPO will expose the costs behind that progress.

The Ring 5 gives Oura a product-led route to new customers, while disease-detection ambitions raise the bar for trust and validation. Its board appointments prepare the company for public ownership, and the confidential filing begins the regulatory process without committing Oura to a date or valuation. If the offering proceeds, investors will be watching revenue growth, subscription economics, ring sales, losses, and the credibility of Oura's medical claims.